{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:08:15Z","timestamp":1793066895380,"version":"4.5.0"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["No. INV-018913"],"award-info":[{"award-number":["No. INV-018913"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020347","name":"Steel and Iron Foundation of Hebei Province","doi-asserted-by":"publisher","award":["No. 71503015"],"award-info":[{"award-number":["No. 71503015"]}],"id":[{"id":"10.13039\/100020347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019053","name":"Capacity Building Plan for some Non-military Universities and Colleges of Shanghai Scientific Committee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013077","name":"National Science and Technology Planning Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013077","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Poverty"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Recent research has suggested that artemisinin and its derivatives may have therapeutic effects on parasites, viruses, tumors, inflammation and skin diseases. This study aimed to review clinical research on artemisinin and its derivatives except anti-malaria and explore possible priority areas for future development.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Relevant articles in English and Chinese published before 28 October 2021 were reviewed. All articles were retrieved and obtained from databases including WanFang, PubMed\/MEDLINE, the Cochrane Library, China National Knowledge International, Embase, OpenGrey, the Grey Literature Report, Grey Horizon, and ClinicalTrials.gov. Studies were selected for final inclusion based on predefined criteria. Information was then extracted and analyzed by region, disease, outcome, and time to identify relevant knowledge gaps.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seventy-seven studies on anti-parasitic (35), anti-tumor (16), anti-inflammatory (12), anti-viral (8), and dermatological treatments (7) focused on the safety and efficacy of artemisinin and its derivatives. The anti-parasitic clinical research developed rapidly, with a large number of trials, rapid clinical progress, and multiple research topics. In contrast, anti-viral research was limited and mainly stayed in phase I clinical trials (37.50%). Most of the studies were conducted in Asia (60%), followed by Africa (27%), Europe (8%), and the Americas (5%). Anti-parasite and anti-inflammatory research were mainly distributed in less developed continents such as Asia and Africa, while cutting-edge research such as anti-tumor has attracted more attention in Europe and the United States. At the safety level, 58 articles mentioned the adverse reactions of artemisinin and its derivatives, with only one study showing a Grade 3 adverse event, while the other studies did not show any related adverse reactions or required discontinuation. Most studies have discovered therapeutic effects of artemisinin or its derivatives on anti-parasitic (27), anti-tumor (9), anti-inflammatory (9) and dermatological treatment (6). However, the efficacy of artemisinin-based combination therapies (ACTs) for parasitic diseases (non-malaria) is still controversial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Recent clinical studies suggest that artemisinin and its derivatives may be safe and effective candidates for anti-tumor, anti-parasitic, anti-inflammatory and dermatological drugs. More phase II\/III clinical trials of artemisinin and its derivatives on antiviral effects are needed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s40249-023-01152-6","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T03:02:01Z","timestamp":1702263721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["New clinical application prospects of artemisinin and its derivatives: a scoping review"],"prefix":"10.1186","volume":"12","author":[{"given":"Yangmu","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,11]]},"reference":[{"key":"1152_CR1","doi-asserted-by":"crossref","unstructured":"Badshah SL, Ullah A, Ahmad N, Almarhoon ZM, Mabkhot Y. Increasing the strength and production of artemisinin and its derivatives. Molecules 2018, 23(1).","DOI":"10.3390\/molecules23010100"},{"issue":"12","key":"1152_CR2","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.pt.2019.09.005","volume":"35","author":"AM Talman","year":"2019","unstructured":"Talman AM, Clain J, Duval R, M\u00e9nard R, Ariey F. Artemisinin bioactivity and resistance in malaria parasites. Trends Parasitol. 2019;35(12):953\u201363.","journal-title":"Trends Parasitol"},{"key":"1152_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/435713","volume":"2015","author":"C Shi","year":"2015","unstructured":"Shi C, Li H, Yang Y, Hou L. Anti-inflammatory and immunoregulatory functions of artemisinin and its derivatives. Mediat Inflamm. 2015;2015: 435713.","journal-title":"Mediat Inflamm"},{"issue":"18","key":"1152_CR4","first-page":"1973","volume":"62","author":"JG Wang","year":"2017","unstructured":"Wang JG, Zhu XX. Advances in the study of artemisinin targets and mechanisms in chemical biology. Kexue Tongbao (Chin Ed). 2017;62(18):1973\u201381 (in Chinese).","journal-title":"Kexue Tongbao (Chin Ed)"},{"key":"1152_CR5","first-page":"52","volume":"04","author":"HQ Guo","year":"2020","unstructured":"Guo HQ, Liu SZ, Wang L, Liu ZY, Wang ZH. Research progress of artemisinin and its derivatives against coccidiosis of chicken. Poult Sci. 2020;04:52\u20136 (in Chinese).","journal-title":"Poult Sci"},{"issue":"2","key":"1152_CR6","volume":"2015","author":"R Isba","year":"2015","unstructured":"Isba R, Zani B, Gathu M, Sinclair D. Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2015;2015(2): Cd011547.","journal-title":"Cochrane Database Syst Rev"},{"key":"1152_CR7","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s12936-015-0919-5","volume":"14","author":"C Naing","year":"2015","unstructured":"Naing C, Whittaker MA, Mak JW, Aung K. A systematic review of the efficacy of a single dose artemisinin-naphthoquine in treating uncomplicated malaria. Malar J. 2015;14:392.","journal-title":"Malar J"},{"key":"1152_CR8","unstructured":"World malaria report 2022. WHO. 2022. https:\/\/www.who.int\/publications\/i\/item\/9789240064898. Accessed 15 Sep 2023."},{"issue":"1","key":"1152_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.cll.2009.10.001","volume":"30","author":"LS Garcia","year":"2010","unstructured":"Garcia LS. Malaria. Clin Lab Med. 2010;30(1):93\u2013129.","journal-title":"Clin Lab Med"},{"key":"1152_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2022.102193","volume":"69","author":"KE Ward","year":"2022","unstructured":"Ward KE, Fidock DA, Bridgford JL. Plasmodium falciparum resistance to artemisinin-based combination therapies. Curr Opin Microbiol. 2022;69: 102193.","journal-title":"Curr Opin Microbiol"},{"key":"1152_CR11","doi-asserted-by":"publisher","DOI":"10.1017\/S1462399409001239","volume":"11","author":"GL Firestone","year":"2009","unstructured":"Firestone GL, Sundar SN. Anticancer activities of artemisinin and its bioactive derivatives. Expert Rev Mol Med. 2009;11: e32.","journal-title":"Expert Rev Mol Med"},{"key":"1152_CR12","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/247597","volume":"2012","author":"MP Crespo-Ortiz","year":"2012","unstructured":"Crespo-Ortiz MP, Wei MQ. Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. J Biomed Biotechnol. 2012;2012: 247597.","journal-title":"J Biomed Biotechnol"},{"issue":"1","key":"1152_CR13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s10637-012-9873-z","volume":"31","author":"HC Lai","year":"2013","unstructured":"Lai HC, Singh NP, Sasaki T. Development of artemisinin compounds for cancer treatment. Invest New Drugs. 2013;31(1):230\u201346.","journal-title":"Invest New Drugs"},{"issue":"1","key":"1152_CR14","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.pharmthera.2013.12.001","volume":"142","author":"WE Ho","year":"2014","unstructured":"Ho WE, Peh HY, Chan TK, Wong WS. Artemisinins: pharmacological actions beyond anti-malarial. Pharmacol Ther. 2014;142(1):126\u201339.","journal-title":"Pharmacol Ther"},{"issue":"12","key":"1152_CR15","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s11655-019-3207-3","volume":"26","author":"Y Li","year":"2020","unstructured":"Li Y, Shan NN, Sui XH. Research progress on artemisinin and its derivatives against hematological malignancies. Chin J Integr Med. 2020;26(12):947\u201355.","journal-title":"Chin J Integr Med"},{"key":"1152_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104829","volume":"157","author":"Y Wang","year":"2020","unstructured":"Wang Y, Wang Y, You F, Xue J. Novel use for old drugs: the emerging role of artemisinin and its derivatives in fibrosis. Pharmacol Res. 2020;157: 104829.","journal-title":"Pharmacol Res"},{"key":"1152_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1748-5908-5-69","volume":"5","author":"D Levac","year":"2010","unstructured":"Levac D, Colquhoun H, O\u2019Brien KK. Scoping studies: advancing the methodology. Implement Sci. 2010;5:69.","journal-title":"Implement Sci"},{"key":"1152_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.phrs.2018.04.025","volume":"133","author":"NS Lam","year":"2018","unstructured":"Lam NS, Long X, Su XZ, Lu F. Artemisinin and its derivatives in treating helminthic infections beyond schistosomiasis. Pharmacol Res. 2018;133:77\u2013100.","journal-title":"Pharmacol Res"},{"issue":"9","key":"1152_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045867","volume":"7","author":"L P\u00e9rez del Villar","year":"2012","unstructured":"P\u00e9rez del Villar L, Burguillo FJ, L\u00f3pez-Ab\u00e1n J, Muro A. Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis. PLoS ONE. 2012;7(9): e45867.","journal-title":"PLoS ONE"},{"issue":"1","key":"1152_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0001-706X(02)00003-7","volume":"82","author":"D De Clercq","year":"2002","unstructured":"De Clercq D, Vercruysse J, Kongs A, Verl\u00e9 P, Dompnier JP, Faye PC. Efficacy of artesunate and praziquantel in Schistosoma haematobium infected schoolchildren. Acta Trop. 2002;82(1):61\u20136.","journal-title":"Acta Trop"},{"issue":"2","key":"1152_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.trstmh.2006.03.003","volume":"101","author":"D Boulanger","year":"2007","unstructured":"Boulanger D, Dieng Y, Cisse B, Remoue F, Capuano F, Dieme JL, et al. Antischistosomal efficacy of artesunate combination therapies administered as curative treatments for malaria attacks. Trans R Soc Trop Med Hyg. 2007;101(2):113\u20136.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"1","key":"1152_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4269\/ajtmh.2003.68.24","volume":"68","author":"EK Goran","year":"2003","unstructured":"Goran EK, J\u00fcrg U, Gnaka HN, Ahoa Y, Guessan NA, et al. Randomized, double-blind, placebo-controlled trial of oral artemether for the prevention of patent Schistosoma haematobium infections. Am J Trop Med Hyg. 2003;68(1):24\u201332.","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"1152_CR23","first-page":"150","volume":"22","author":"HY Hua","year":"2010","unstructured":"Hua HY, An N, Wu HZ, Gao ZL, Zhang Y, Liang YS. Clinical trials on preventive effect of artesunate against reinfection of Schistosoma japonicum. Zhongguo Xuexichongbing Fangzhi Zazhi. 2010;22(2):150\u20132 (in Chinese).","journal-title":"Zhongguo Xuexichongbing Fangzhi Zazhi"},{"issue":"4","key":"1152_CR24","first-page":"272","volume":"109","author":"S Xiao","year":"1996","unstructured":"Xiao S, Shi Z, Zhuo S, Wang C, Zhang Z, Chu B, et al. Field studies on the preventive effect of oral artemether against schistosomal infection. Chin Med J. 1996;109(4):272\u20135.","journal-title":"Chin Med J"},{"issue":"2","key":"1152_CR25","first-page":"123","volume":"111","author":"Y Song","year":"1998","unstructured":"Song Y, Xiao S, Wu W, Zhang S, Xie H, Xu X, et al. Preventive effect of artemether on schistosome infection. Chin Med J. 1998;111(2):123\u20137.","journal-title":"Chin Med J"},{"issue":"2\u20133","key":"1152_CR26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.actatropica.2005.07.013","volume":"96","author":"YS Li","year":"2005","unstructured":"Li YS, Chen HG, He HB, Hou XY, Ellis M, McManus DP. A double-blind field trial on the effects of artemether on Schistosoma japonicum infection in a highly endemic focus in southern China. Acta Trop. 2005;96(2\u20133):184\u201390.","journal-title":"Acta Trop"},{"key":"1152_CR27","first-page":"100","volume":"2","author":"ZH Yi","year":"2000","unstructured":"Yi ZH, Lu M, Feng DC, Wang ZH, Xiang CP, Gou ZQ, et al. Clinical observation on prevention of schistosomiasis by oral artesunate in people exposed to epidemic water for a short time. Zhongguo Xuexichongbing Fangzhi Zazhi. 2000;2:100\u20131 (in Chinese).","journal-title":"Zhongguo Xuexichongbing Fangzhi Zazhi"},{"issue":"10","key":"1152_CR28","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1086\/324004","volume":"184","author":"S Borrmann","year":"2001","unstructured":"Borrmann S, Szlez\u00e1k N, Faucher JF, Matsiegui PB, Neubauer R, Binder RK, et al. Artesunate and praziquantel for the treatment of Schistosoma haematobium infections: a double-blind, randomized, placebo-controlled study. J Infect Dis. 2001;184(10):1363\u20136.","journal-title":"J Infect Dis"},{"key":"1152_CR29","first-page":"39","volume":"01","author":"DD Lin","year":"1999","unstructured":"Lin DD, Zhang SJ, Liu YM, Li SW, Wu LJ, Gao ZL, et al. Field observation on the prophylaxis of artesunate with 15 days interval against infection of schtstosoma japonicum. Zhongguo Renshou Gonghuanbing Zazhi. 1999;01:39\u201340 (in Chinese).","journal-title":"Zhongguo Renshou Gonghuanbing Zazhi"},{"key":"1152_CR30","first-page":"48","volume":"01","author":"RG Lu","year":"1997","unstructured":"Lu RG, Wang XY, Li ZH, Yan JL, Huang YN, Liu ZD, et al. Clinical validation of artesunate against Schistosomiasis japonicum. Jishengchongbing Yu Ganranxingjibing. 1997;01:48 (in Chinese).","journal-title":"Jishengchongbing Yu Ganranxingjibing"},{"key":"1152_CR31","first-page":"68","volume":"02","author":"MS Xu","year":"1998","unstructured":"Xu MS, Zhang SQ, Wang TP, Fang GR, Wang QZ, He JX, et al. Field appliance of oral artesunate for prevention of schistosomiasis japonica. Redaibing Yu Jishengchongxue. 1998;02:68\u201371 (in Chinese).","journal-title":"Redaibing Yu Jishengchongxue"},{"issue":"003","key":"1152_CR32","first-page":"214","volume":"012","author":"HY Liu","year":"1999","unstructured":"Liu HY, Li SW. Observation on the prevention of schistosomiasis japonica by administration of artesunate long term. J Pathogen Biol. 1999;012(003):214\u20135 (in Chinese).","journal-title":"J Pathogen Biol"},{"key":"1152_CR33","first-page":"57","volume":"03","author":"GY Lu","year":"2000","unstructured":"Lu GY, Lin GJ, Sun MX, Jiang J, Cui JF, Wu QZ, et al. Optimization of oral artesunate to prevent schistosoma schistosoma infection. J Pathogen Biol. 2000;03:57\u20139 (in Chinese).","journal-title":"J Pathogen Biol"},{"key":"1152_CR34","first-page":"68","volume":"02","author":"SJ Zhang","year":"2000","unstructured":"Zhang SJ, Lin DD, Liu YM, Liu HY, Liu ZD, Hu LS, et al. Clinical trials on preventive effect of artesunate on Schistosomiasis Japonica. Xiandai Zhenduan Yu Zhiliao. 2000;02:68\u201372 (in Chinese).","journal-title":"Xiandai Zhenduan Yu Zhiliao"},{"key":"1152_CR35","unstructured":"Hou XY. Clinical study on acute schistosomiasis japonica treatment with artemether and praziquantel. Master. Central South University; 2006 (in Chinese)."},{"key":"1152_CR36","first-page":"323","volume":"06","author":"LJ Wu","year":"1995","unstructured":"Wu LJ, Li SW, Xuan XY, Xu PS, Liu ZD, Hu LS, et al. Field application of artesunate in prophylaxis of schistosomiasis: an observation of 346 cases. Zhongguo Xuexichongbing Fangzhi Zazhi. 1995;06:323\u20137 (in Chinese).","journal-title":"Zhongguo Xuexichongbing Fangzhi Zazhi"},{"key":"1152_CR37","first-page":"142","volume":"03","author":"ZD Liu","year":"1996","unstructured":"Liu ZD, Hu F, Zhou SY, Liu YM, Hu LS, Su LH, et al. Clinical validation of artesunate against Schistosomiasis japonicum in Rocky Mountains. Zhongguo Xuexichongbing Fangzhi Zazhi. 1996;03:142\u20135 (in Chinese).","journal-title":"Zhongguo Xuexichongbing Fangzhi Zazhi"},{"issue":"1","key":"1152_CR38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4269\/ajtmh.2003.68.24","volume":"68","author":"EK N'Goran","year":"2003","unstructured":"N\u2019Goran EK, Utzinger J, Gnaka HN, Yapi A, N\u2019Guessan NA, Kigbafori SD, et al. Randomized, double-blind, placebo-controlled trial of oral artemether for the prevention of patent Schistosoma haematobium infections. Am J Trop Med Hyg. 2003;68(1):24\u201332.","journal-title":"Am J Trop Med Hyg"},{"issue":"9212","key":"1152_CR39","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/S0140-6736(00)02114-0","volume":"355","author":"J Utzinger","year":"2000","unstructured":"Utzinger J, N\u2019Goran EK, N\u2019Dri A, Lengeler C, Xiao S, Tanner M. Oral artemether for prevention of Schistosoma mansoni infection: randomised controlled trial. Lancet. 2000;355(9212):1320\u20135.","journal-title":"Lancet"},{"issue":"4","key":"1152_CR40","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00436-010-1944-5","volume":"107","author":"HY Hua","year":"2010","unstructured":"Hua HY, Liang YS, Zhang Y, Wei JF, Guo HX. The sensitivity of artesunate against Schistosoma japonicum decreased after 10 years of use in China. J Parasitol Res. 2010;107(4):873\u20138.","journal-title":"J Parasitol Res"},{"issue":"4","key":"1152_CR41","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s00436-011-2641-8","volume":"110","author":"R Liu","year":"2012","unstructured":"Liu R, Dong HF, Jiang MS. The sensitivity of artesunate against Schistosoma japonicum decreased after 10 years of use in China? Parasitol Res. 2012;110(4):1563\u20134.","journal-title":"Parasitol Res"},{"key":"1152_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006732","author":"MS Sissoko","year":"2009","unstructured":"Sissoko MS, Dabo A, Traor\u00e9 H, Diallo M, Traor\u00e9 B, Konat\u00e9 D, et al. Efficacy of artesunate + sulfamethoxypyrazine\/pyrimethamine versus praziquantel in the treatment of Schistosoma haematobium in children. PLoS ONE. 2009. https:\/\/doi.org\/10.1371\/journal.pone.0006732.","journal-title":"PLoS ONE"},{"issue":"2","key":"1152_CR43","first-page":"103","volume":"18","author":"DG Wang","year":"2012","unstructured":"Wang DG, Wang GH, Wang HL, Wang B, Xu AR, Li XS, et al. A control study of artemether auxiliary treatment for schizophrenia with toxoplasmosis gondii antibody positive. Linchuang Xinshen Jibing Zazhi. 2012;18(2):103\u20135 (in Chinese).","journal-title":"Linchuang Xinshen Jibing Zazhi"},{"key":"1152_CR44","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.actatropica.2016.02.015","volume":"158","author":"H Elmorshedy","year":"2016","unstructured":"Elmorshedy H, Tanner M, Bergquist RN, Sharaf S, Barakat R. Prophylactic effect of artemether on human schistosomiasis mansoni among Egyptian children: a randomized controlled trial. Acta Trop. 2016;158:52\u20138.","journal-title":"Acta Trop"},{"issue":"1","key":"1152_CR45","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.trstmh.2008.08.002","volume":"103","author":"PC Inyang-Etoh","year":"2009","unstructured":"Inyang-Etoh PC, Ejezie GC, Useh MF, Inyang-Etoh EC. Efficacy of a combination of praziquantel and artesunate in the treatment of urinary schistosomiasis in Nigeria. Trans R Soc Trop Med Hyg. 2009;103(1):38\u201344.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"9","key":"1152_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0008619","volume":"14","author":"RH Mnkugwe","year":"2020","unstructured":"Mnkugwe RH, Minzi O. Kinung\u2019hi S, Kamuhabwa A, Aklillu E: Efficacy and safety of praziquantel and dihydroartemisinin piperaquine combination for treatment and control of intestinal schistosomiasis: a randomized, non-inferiority clinical trial. PLoS Negl Trop Dis. 2020;14(9):1\u201318.","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"1152_CR47","first-page":"99","volume":"18","author":"XY Hou","year":"2006","unstructured":"Hou XY, Li YS, Luo XS, He KY, Yu XL, Fu X, et al. Clinical study on acute schistosomiasis japonica treatment with artemether and praziquantel. Zhongguo Xuexichongbing Fangzhi Zazhi. 2006;18(2):99\u2013102 (in Chinese).","journal-title":"Zhongguo Xuexichongbing Fangzhi Zazhi"},{"issue":"9","key":"1152_CR48","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1473-3099(10)70161-4","volume":"10","author":"CO Obonyo","year":"2010","unstructured":"Obonyo CO, Muok EMO, Mwinzi PNM. Efficacy of artesunate with sulfalene plus pyrimethamine versus praziquantel for treatment of Schistosoma mansoni in Kenyan children: an open-label randomised controlled trial. Lancet Infect Dis. 2010;10(9):603\u201311.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"1152_CR49","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jpsychires.2014.02.016","volume":"53","author":"HL Wang","year":"2014","unstructured":"Wang HL, Xiang YT, Li QY, Wang XP, Liu ZC, Hao SS, et al. The effect of artemether on psychotic symptoms and cognitive impairment in first-episode, antipsychotic drug-naive persons with schizophrenia seropositive to Toxoplasma gondii. J Psychiatr Res. 2014;53(1):119\u201324.","journal-title":"J Psychiatr Res"},{"issue":"2\u20133","key":"1152_CR50","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.schres.2011.04.010","volume":"129","author":"F Dickerson","year":"2011","unstructured":"Dickerson F, Stallings C, Vaughan C, Origoni A, Goga J, Khushalani S, et al. Artemisinin reduces the level of antibodies to gliadin in schizophrenia. Schizophr Res. 2011;129(2\u20133):196\u2013200.","journal-title":"Schizophr Res"},{"issue":"3","key":"1152_CR51","doi-asserted-by":"publisher","first-page":"388","DOI":"10.4269\/ajtmh.2008.78.388","volume":"78","author":"TH Tran","year":"2008","unstructured":"Tran TH, Ng TT, Nguyen HM, Hoang DD, Nguyen TD, Nguyen TH, et al. A randomized controlled pilot study of artesunate versus triclabendazole for human fascioliasis in central Vietnam. Am J Trop Med Hyg. 2008;78(3):388\u201392.","journal-title":"Am J Trop Med Hyg"},{"key":"1152_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001285","author":"J Keiser","year":"2011","unstructured":"Keiser J, Sayed H, El-Ghanam M, Sabry H, Anani S, El-Wakeel A, et al. Efficacy and safety of artemether in the treatment of chronic fascioliasis in Egypt: exploratory phase-2 trials. PLoS Negl Trop Dis. 2011. https:\/\/doi.org\/10.1371\/journal.pntd.0001285.","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"1152_CR53","first-page":"767","volume":"18","author":"T Efferth","year":"2001","unstructured":"Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. The anti-malarial artesunate is also active against cancer. Int J Oncol. 2001;18(4):767\u201373.","journal-title":"Int J Oncol"},{"key":"1152_CR54","unstructured":"Luo YC. Effect of artesunate hepatic artery infusion on immune function in patients with primary liver cancer. Master. Guangzhou University of Chinese Medicine; 2008 (in Chinese)."},{"key":"1152_CR55","doi-asserted-by":"publisher","DOI":"10.3736\/jcim20080206","author":"S-Q Yu","year":"2008","unstructured":"Yu S-Q, Zhang Z-Y. Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled trial. Zhong Xi Yi Jie He Xue Bao. 2008. https:\/\/doi.org\/10.3736\/jcim20080206.","journal-title":"Zhong Xi Yi Jie He Xue Bao"},{"key":"1152_CR56","unstructured":"Zhang YY. Clinical efficacy and safety of artesunate in the treatment of advanced retinoblastoma. Master. Anhui Medical University; 2015 (in Chinese)."},{"issue":"1","key":"1152_CR57","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ebiom.2014.11.010","volume":"2","author":"S Krishna","year":"2015","unstructured":"Krishna S, Ganapathi S, Ster IC, Saeed MEM, Cowan M, Finlayson C, et al. A randomised, double blind, placebo-controlled pilot study of oral artesunate therapy for colorectal cancer. EBioMedicine. 2015;2(1):82\u201390.","journal-title":"EBioMedicine"},{"issue":"2","key":"1152_CR58","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10549-017-4261-1","volume":"164","author":"C von Hagens","year":"2017","unstructured":"von Hagens C, Walter-Sack I, Goeckenjan M, Osburg J, Storch-Hagenlocher B, Sertel S, et al. Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33\/2). Breast Cancer Res Treat. 2017;164(2):359\u201369.","journal-title":"Breast Cancer Res Treat"},{"key":"1152_CR59","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.phymed.2018.09.178","volume":"54","author":"C von Hagens","year":"2019","unstructured":"von Hagens C, Walter-Sack I, Goeckenjan M, Storch-Hagenlocher B, Sertel S, Els\u00e4sser M, et al. Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33\/2). Phytomedicine. 2019;54:140\u20138.","journal-title":"Phytomedicine"},{"key":"1152_CR60","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ygyno.2020.06.078","volume":"159","author":"CL Trimble","year":"2020","unstructured":"Trimble CL, Levinson K, Maldonado L, Donovan M, Clark KT, Fu J, et al. A first-in-human proof-of-concept trial of intravaginal artesunate to treat cervical intraepithelial neoplasia (CIN2\/3). Gynecol Oncol. 2020;159:37.","journal-title":"Gynecol Oncol"},{"issue":"12","key":"1152_CR61","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1007\/s00228-014-1754-2","volume":"70","author":"T Ericsson","year":"2014","unstructured":"Ericsson T, Blank A, Von Hagens C, Ashton M, \u00c4bel\u00f6 A. Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer. Eur J Clin Pharmacol. 2014;70(12):1453\u201363.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"1152_CR62","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00280-018-3533-8","volume":"81","author":"JF Deeken","year":"2018","unstructured":"Deeken JF, Wang H, Hartley M, Cheema AK, Smaglo B, Hwang JJ, et al. A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol. 2018;81(3):587\u201396.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"1152_CR63","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00280-016-2960-7","volume":"77","author":"M K\u00f6nig","year":"2016","unstructured":"K\u00f6nig M, Von Hagens C, Hoth S, Baumann I, Walter-Sack I, Edler L, et al. Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase i study. Cancer Chemother Pharmacol. 2016;77(2):413\u201327.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"32","key":"1152_CR64","first-page":"108","volume":"12","author":"WJ Zhou","year":"2017","unstructured":"Zhou WJ. Study on the clinical efficacy of anti-tumor angiogenesis drugs. China Pract Med. 2017;12(32):108\u20139 (in Chinese).","journal-title":"China Pract Med"},{"key":"1152_CR65","unstructured":"Zhang XJ. Therapeutic effect of artesunate on acute leukemia and its effect on intracellular calcium concentration. Master. Guangzhou University of Chinese Medicine; 2008 (in Chinese)."},{"issue":"5","key":"1152_CR66","first-page":"517","volume":"31","author":"M Wang","year":"2016","unstructured":"Wang M, Luo HJ, Lin Y. The chemotherapy effect and safety of artesunate\/cisplatin-paclitaxel for ovarian cancer. Xibei Yaoxue Zazhi. 2016;31(5):517\u20139 (in Chinese).","journal-title":"Xibei Yaoxue Zazhi"},{"key":"1152_CR67","first-page":"934","volume":"7","author":"XP Xiao","year":"2015","unstructured":"Xiao XP, Zhang ZY, Yu SQ, Zhou SX. The curative effect of chemotherapy combined with sequential administration of artesu-nate in non - small cell lung cancer. Mod Oncol. 2015;7:934\u20136.","journal-title":"Mod Oncol"},{"issue":"1","key":"1152_CR68","first-page":"643","volume":"13","author":"H Zhang","year":"2009","unstructured":"Zhang H. Analysis of 134 cases of uveitis complicated by malaria. Chin N Med. 2009;13(1):643\u20134 (in Chinese).","journal-title":"Chin N Med"},{"key":"1152_CR69","first-page":"572","volume":"4","author":"DZ Li","year":"2015","unstructured":"Li DZ. Observation on the efficacy of artesunate boric acid powder combined with microwave irradiation in the treatment of chronic suppurative otitis media in malaria area. Zhongguo Yaowu Yu Linchuang. 2015;4:572\u20133 (in Chinese).","journal-title":"Zhongguo Yaowu Yu Linchuang"},{"issue":"4","key":"1152_CR70","first-page":"417","volume":"32","author":"YR Lin","year":"2020","unstructured":"Lin YR, Wu FY, Xie HZ, Song XL, Zhu QD, Wei J, et al. Clinical study of artesunate in the treatment of coronavirus disease 2019. Zhonghua Weizhongbing Jijiu Yixue. 2020;32(4):417\u201320 (in Chinese).","journal-title":"Zhonghua Weizhongbing Jijiu Yixue"},{"key":"1152_CR71","unstructured":"Liu HJ. Clinical study of artesunate in the treatment of systemic lupus erythematosus. Master. Guangzhou University of Chinese Medicine; 2002 (in Chinese)."},{"issue":"3","key":"1152_CR72","first-page":"169","volume":"22","author":"L Lu","year":"2002","unstructured":"Lu L. Study on effect of Cordyceps Sinensis and artemisinin in preventing recurrence of lupus nephritis. Zhongguo Zhongxiyi Jiehe Zazhi. 2002;22(3):169\u201371 (in Chinese).","journal-title":"Zhongguo Zhongxiyi Jiehe Zazhi"},{"issue":"5","key":"1152_CR73","first-page":"666","volume":"13","author":"AH Du","year":"2004","unstructured":"Du AH, He YQ, Chen LP. Clinical nursing of severe lupus nephritis treated by combination of traditional Chinese and Western Medicine. Xiandai Zhongxiyi Jiehe Zazhi. 2004;13(5):666\u20137 (in Chinese).","journal-title":"Xiandai Zhongxiyi Jiehe Zazhi"},{"issue":"5","key":"1152_CR74","first-page":"645","volume":"27","author":"XJ Cui","year":"2007","unstructured":"Cui XJ, Wang YY, Hou XQ, Pan L, Fu JX. Clinical observation of artesunate in the treatment of rheumatoid arthritis. Zhongguo Yiyuan Yaoxue Zazhi. 2007;27(5):645\u20136 (in Chinese).","journal-title":"Zhongguo Yiyuan Yaoxue Zazhi"},{"issue":"9","key":"1152_CR75","first-page":"457","volume":"37","author":"S Wei","year":"2008","unstructured":"Wei S, Xu GG. Clinical observation of artesunate in the treatment of rheumatoid arthritis. Shanxi Yiyao Zazhi. 2008;37(9):457\u20138 (in Chinese).","journal-title":"Shanxi Yiyao Zazhi"},{"issue":"7","key":"1152_CR76","first-page":"1673","volume":"22","author":"XX Huang","year":"2011","unstructured":"Huang XX. Clinical study on the effect of artesunate on immune function in patients with lupus nephritis. Shizhen Guoyi Guoyao. 2011;22(7):1673\u20134 (in Chinese).","journal-title":"Shizhen Guoyi Guoyao"},{"issue":"2","key":"1152_CR77","first-page":"8","volume":"16","author":"YJ Zhao","year":"2016","unstructured":"Zhao YJ, Liu XR. Clinical observation on 25 cases of VKH syndrome treated by artemether soft capsule combined with glucocorticoid. Pract Clin J Integr Tradit Chin West Med. 2016;16(2):8-10,16 Chinese.","journal-title":"Pract Clin J Integr Tradit Chin West Med"},{"issue":"6","key":"1152_CR78","first-page":"336","volume":"11","author":"JX Zhong","year":"2000","unstructured":"Zhong JX, Liu YM, Liu HJ, Yang DF, Lin XD, Fu CL, et al. Safety of artesunate in the treatment of systemic lupus erythematosus. Zhongyao Xinyao Yu Linchuang Yaoli. 2000;11(6):336\u2013336 (in Chinese).","journal-title":"Zhongyao Xinyao Yu Linchuang Yaoli"},{"issue":"6","key":"1152_CR79","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1097\/QAD.0b013e32835cae3b","volume":"27","author":"M Lamorde","year":"2013","unstructured":"Lamorde M, Byakika-Kibwika P, Mayito J, Nabukeera L, Ryan M, Hanpithakpong W, et al. Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment. AIDS. 2013;27(6):961\u20135.","journal-title":"AIDS"},{"key":"1152_CR80","first-page":"173","volume":"3","author":"QB Yu","year":"1996","unstructured":"Yu QB, Jin HL. Systemic lupus erythematosus treated with artesunate. Bengbu Yixueyuan Xuebao. 1996;3:173\u20134 (in Chinese).","journal-title":"Bengbu Yixueyuan Xuebao"},{"issue":"5","key":"1152_CR81","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1093\/jac\/dkr596","volume":"67","author":"P Byakika-Kibwika","year":"2012","unstructured":"Byakika-Kibwika P, Lamorde M, Okaba-Kayom V, Mayanja-Kizza H, Katabira E, Hanpithakpong W, et al. Lopinavir\/ritonavir significantly influences pharmacokinetic exposure of artemether\/lumefantrine in HIV-infected Ugandan adults. J Antimicrob Chemother. 2012;67(5):1217\u201323.","journal-title":"J Antimicrob Chemother"},{"key":"1152_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1345-1","author":"T Kredo","year":"2016","unstructured":"Kredo T, Mauff K, Workman L, Vander Walt JS, Wiesner L, et al. The interaction between artemether-lumefantrine and lopinavir\/ritonavir-based antiretroviral therapy in HIV-1 infected patients. BMC Infect Dis. 2016. https:\/\/doi.org\/10.1186\/s12879-016-1345-1.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"1152_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2193-9616-1-4","volume":"1","author":"M Siccardi","year":"2013","unstructured":"Siccardi M, Olagunju A, Seden K, Ebrahimjee F, Rannard S, Back D, et al. Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. In Silico Pharmacol. 2013;1(1):1\u20138.","journal-title":"In Silico Pharmacol"},{"issue":"1","key":"1152_CR84","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jcv.2013.06.008","volume":"58","author":"G Soren","year":"2013","unstructured":"Soren G. An artesunate-containing antimalarial treatment regimen did not suppress cytomegalovirus viremia. J Clin Virol. 2013;58(1):276\u20138.","journal-title":"J Clin Virol"},{"key":"1152_CR85","first-page":"251","volume":"4","author":"H Chen","year":"1991","unstructured":"Chen H, Gao YX. Artesunate therapy in eczema-dermatitis and photoallergic skin diseases (preliminary observation). Bengbu Yixueyuan Xuebao. 1991;4:251\u20132 (in Chinese).","journal-title":"Bengbu Yixueyuan Xuebao"},{"key":"1152_CR86","first-page":"25","volume":"5","author":"QB Yu","year":"1997","unstructured":"Yu QB, Jin HL. Clinical analysis of 90 cases of dermatosis treated with artesunate. Bengbu Yixueyuan Xuebao. 1997;5:25\u20136 (in Chinese).","journal-title":"Bengbu Yixueyuan Xuebao"},{"issue":"3","key":"1152_CR87","first-page":"330","volume":"29","author":"T Li","year":"2015","unstructured":"Li T, Hu Y, Yu AH, Chen XM, Zhang HQ, Wang GJ. Clinical research of the efficacy of artesunate in 31 patients with rosacea. Zhongguo Pifu Xingbingxue Zazhi. 2015;29(3):330\u20132 (in Chinese).","journal-title":"Zhongguo Pifu Xingbingxue Zazhi"},{"issue":"8","key":"1152_CR88","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1080\/09546634.2019.1610549","volume":"30","author":"GJ Wang","year":"2019","unstructured":"Wang GJ, Gao XY, Wu Y, He HQ, Yu Y, Qin HH, et al. Evaluation of the efficacy and tolerance of artemether emulsion for the treatment of papulopustular rosacea: a randomized pilot study. J Dermatolog Treat. 2019;30(8):809\u201312.","journal-title":"J Dermatolog Treat"},{"issue":"7","key":"1152_CR89","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1080\/09546634.2019.1710447","volume":"32","author":"WT Shen","year":"2021","unstructured":"Shen WT, Wu Y, He HQ, Yu Y, Qin HH, Fei JB, et al. Efficacy and safety of artemether emulsion for the treatment of mild-to-moderate acne vulgaris: a randomized pilot study. J Dermatolog Treat. 2021;32(7):762\u20135.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"1152_CR90","first-page":"55","volume":"27","author":"DQ Deng","year":"2006","unstructured":"Deng DQ, Chen H, Zhou XO, Li HY, Xie HY, Zhang PL. Clinical observation of polymorphous light eruption and chronic actinic dermatitis treated with artemtherin. Kunming Yike Daxue Xuebao. 2006;27(6):55\u20138, 61 (in Chinese).","journal-title":"Kunming Yike Daxue Xuebao"},{"issue":"1","key":"1152_CR91","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.eng.2018.11.011","volume":"5","author":"J Wang","year":"2019","unstructured":"Wang J, Xu C, Wong YK, Li Y, Liao F, Jiang T, et al. Artemisinin, the magic drug discovered from traditional Chinese medicine\u2014sciencedirect. Engineering. 2019;5(1):32\u20139.","journal-title":"Engineering"},{"issue":"02","key":"1152_CR92","first-page":"599","volume":"53","author":"WQ Jiang","year":"2022","unstructured":"Jiang WQ, Dong YJ, Zhou FJ, Chen JP, Zhou YT, Tian CW, et al. Research progress of artemisinin and its derivatives. Zhongcaoyao. 2022;53(02):599\u2013608 (in Chinese).","journal-title":"Zhongcaoyao"},{"issue":"5","key":"1152_CR93","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1179\/000349804225003460","volume":"98","author":"PC Inyang-Etoh","year":"2004","unstructured":"Inyang-Etoh PC, Ejezie GC, Useh MF, Inyang-Etoh EC. Efficacy of artesunate in the treatment of urinary schistosomiasis, in an endemic community in Nigeria. Ann Trop Med Parasitol. 2004;98(5):491\u20139.","journal-title":"Ann Trop Med Parasitol"},{"issue":"19","key":"1152_CR94","first-page":"3351","volume":"47","author":"TJ Zhang","year":"2016","unstructured":"Zhang TJ, Wang YF, Liu D, Li LG, Guo RX, Shi QW, et al. History of natural medicine chemistry: artemisinin\u2014a monument of traditional Chinese medicine research. Zhongcaoyao. 2016;47(19):3351\u201361 (in Chinese).","journal-title":"Zhongcaoyao"},{"issue":"6","key":"1152_CR95","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1002\/med.21580","volume":"39","author":"X Sun","year":"2019","unstructured":"Sun X, Yan P, Zou C, Wong YK, Shu Y, Lee YM, Zhang C, Yang ND, Wang J, Zhang J. Targeting autophagy enhances the anticancer effect of artemisinin and its derivatives. Med Res Rev. 2019;39(6):2172\u201393.","journal-title":"Med Res Rev"},{"key":"1152_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107706","volume":"216","author":"Y Augustin","year":"2020","unstructured":"Augustin Y, Staines HM, Krishna S. Artemisinins as a novel anti-cancer therapy: targeting a global cancer pandemic through drug repurposing. Pharmacol Ther. 2020;216: 107706.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"1152_CR97","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s12250-021-00349-z","volume":"36","author":"J Luo","year":"2021","unstructured":"Luo J, Zhang Y, Wang Y, Liu Q, Li J, He H, Luo Y, Huang S, Guo X. Artesunate and dihydroartemisinin inhibit rabies virus replication. Virol Sin. 2021;36(4):721\u20139.","journal-title":"Virol Sin"},{"key":"1152_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.parint.2020.102218","volume":"80","author":"L Mach\u00edn","year":"2021","unstructured":"Mach\u00edn L, N\u00e1poles R, Gille L, Monzote L. Leishmania amazonensis response to artemisinin and derivatives. Parasitol Int. 2021;80: 102218.","journal-title":"Parasitol Int"},{"key":"1152_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2021.114797","volume":"284","author":"MS Nair","year":"2022","unstructured":"Nair MS, Huang Y, Fidock DA, Towler MJ, Weathers PJ. Artemisia annua L. hot-water extracts show potent activity in vitro against Covid-19 variants including delta. J Ethnopharmacol. 2022;284: 114797.","journal-title":"J Ethnopharmacol"},{"issue":"01","key":"1152_CR100","first-page":"64","volume":"53","author":"YL Chen","year":"2023","unstructured":"Chen YL, Guo Y. Epidemic characteristics and influencing factors of parasitic diseases. Gansu Anim Husb Vet Med. 2023;53(01):64\u20136 (in Chinese).","journal-title":"Gansu Anim Husb Vet Med"},{"issue":"03","key":"1152_CR101","first-page":"163","volume":"14","author":"YJ Liang","year":"2021","unstructured":"Liang YJ, Peng Y, Han XP. Research progress of artemisinin and its derivatives in dermatosis. J Pract Dermatol. 2021;14(03):163\u20136 (in Chinese).","journal-title":"J Pract Dermatol"},{"key":"1152_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.soh.2023.100009","volume":"1","author":"H-M Li","year":"2022","unstructured":"Li H-M, Arthur Djibougou D, Lu S-N, Lv S, Zongo D, Wang D-Q, et al. Strengthening capacity-building in malaria and schistosomiasis control under China-Africa cooperation: assessing a case study of Burkina Faso. Sci One Health. 2022;1: 100009.","journal-title":"Sci One Health"},{"key":"1152_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.soh.2023.100042","volume":"2","author":"Z-Y Guo","year":"2023","unstructured":"Guo Z-Y, Zheng J, Li S-Z, Zhou X-N. Orientation of One Health development: think globally and act locally. Sci One Health. 2023;2: 100042.","journal-title":"Sci One Health"},{"issue":"2","key":"1152_CR104","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.201900240","volume":"353","author":"B Zhang","year":"2020","unstructured":"Zhang B. Artemisinin-derived dimers as potential anticancer agents: current developments, action mechanisms, and structure-activity relationships. Arch Pharm (Weinheim). 2020;353(2): e1900240.","journal-title":"Arch Pharm (Weinheim)"},{"key":"1152_CR105","first-page":"41","volume":"02","author":"ZH Lou","year":"2023","unstructured":"Lou ZH, Bao JF, Guo JC. Artemisinin derivatives may assist in the treatment of liver cancer. Liver Doctor. 2023;02:41\u20132 (in Chinese).","journal-title":"Liver Doctor"},{"issue":"11","key":"1152_CR106","first-page":"58","volume":"21","author":"XD Shen","year":"2022","unstructured":"Shen XD, Cao YO, Su C. Research progress on the effect of artemisinin and its derivatives on gastrointestinal tumors. J Tradit Chin Med. 2022;21(11):58\u201360 (in Chinese).","journal-title":"J Tradit Chin Med"},{"issue":"03","key":"1152_CR107","first-page":"463","volume":"20","author":"LJ Zhang","year":"2014","unstructured":"Zhang LJ, Zhuang KY. Research and application of artemisinin and its derivatives in dermatology. Yixue Zongshu. 2014;20(03):463\u20135 (in Chinese).","journal-title":"Yixue Zongshu"},{"issue":"01","key":"1152_CR108","first-page":"232","volume":"33","author":"L Jiang","year":"2018","unstructured":"Jiang L, Sun LY. General situation of research on Artemisia annua and its derivatives in the treatment of skin diseases. Zhonghua Zhongyiyao Zazhi. 2018;33(01):232\u20135 (in Chinese).","journal-title":"Zhonghua Zhongyiyao Zazhi"},{"issue":"04","key":"1152_CR109","first-page":"606","volume":"43","author":"GM Liu","year":"2020","unstructured":"Liu GM, Cai N, Xie J, Xin C, Li RM, Zhou HY, et al. Application of artemisinin and its derivatives in the treatment of COVID-19. Yaowu Pingjia Yanjiu. 2020;43(04):606\u201312 (in Chinese).","journal-title":"Yaowu Pingjia Yanjiu"},{"issue":"24","key":"1152_CR110","first-page":"6053","volume":"45","author":"YM Yang","year":"2020","unstructured":"Yang YM, Chen LN, Qu SQ, Deng QS, Liu H, Wang Q, et al. Based on the cardiovascular protective effects of artemisinin and its derivatives, the feasibility of artemisinin in the intervention of cardiovascular complications in COVID-19 was discussed. Zhongguo Zhongyao Zazhi. 2020;45(24):6053\u201364 (in Chinese).","journal-title":"Zhongguo Zhongyao Zazhi"},{"issue":"08","key":"1152_CR111","first-page":"2077","volume":"43","author":"W Liu","year":"2020","unstructured":"Liu W, Gong PY, Gu J, Yuan ZX. Application of traditional Chinese medicine with antipyretic, anti-inflammatory and immunomodulatory effects in the treatment of COVID-19 (COVID-19). Zhongyaocai. 2020;43(08):2077\u201383 (in Chinese).","journal-title":"Zhongyaocai"},{"key":"1152_CR112","unstructured":"Guo FQ. Preparation and preliminary evaluation of dihydroartemisinin sustained release tablets. M.s. China Acad Chin Med Sci. 2020 (in Chinese)."},{"issue":"7","key":"1152_CR113","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","volume":"12","author":"D Sun","year":"2022","unstructured":"Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? Acta Pharm Sin B. 2022;12(7):3049\u201362.","journal-title":"Acta Pharm Sin B"},{"key":"1152_CR114","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.ejmech.2018.12.007","volume":"163","author":"A Kumari","year":"2019","unstructured":"Kumari A, Karnatak M, Singh D, Shankar R, Jat JL, Sharma S, Yadav D, Shrivastava R, Verma VP. Current scenario of artemisinin and its analogues for antimalarial activity. Eur J Med Chem. 2019;163:804\u201329.","journal-title":"Eur J Med Chem"},{"issue":"13","key":"1152_CR115","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1016\/j.phymed.2015.10.003","volume":"22","author":"T Efferth","year":"2015","unstructured":"Efferth T, Zacchino S, Georgiev MI, Liu L, Wagner H, Panossian A. Nobel Prize for artemisinin brings phytotherapy into the spotlight. Phytomedicine. 2015;22(13):A1\u20133.","journal-title":"Phytomedicine"},{"issue":"4","key":"1152_CR116","first-page":"349","volume":"28","author":"YM Huang","year":"2016","unstructured":"Huang YM, Cao J. China\u2019s contribution to the research and development of medical products against parasitic diseases: inspiration from the 2015 Nobel Prize in Physiology or Medicine. Zhongguo Xuexichongbing Fangzhi Zazhi. 2016;28(4):349\u201352 (in Chinese).","journal-title":"Zhongguo Xuexichongbing Fangzhi Zazhi"},{"issue":"9","key":"1152_CR117","doi-asserted-by":"publisher","first-page":"15058","DOI":"10.3390\/molecules190915058","volume":"19","author":"YX Liu","year":"2014","unstructured":"Liu YX, Wu W, Liang YJ, Jie ZL, Wang H, Wang W, et al. New uses for old drugs: the tale of artemisinin derivatives in the elimination of schistosomiasis japonica in China. Molecules. 2014;19(9):15058\u201374.","journal-title":"Molecules"},{"issue":"1","key":"1152_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/03602532.2015.1124888","volume":"48","author":"BL Ma","year":"2016","unstructured":"Ma BL, Ma YM. Pharmacokinetic herb-drug interactions with traditional Chinese medicine: progress, causes of conflicting results and suggestions for future research. Drug Metab Rev. 2016;48(1):1\u201326.","journal-title":"Drug Metab Rev"},{"key":"1152_CR119","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.930813","volume":"13","author":"S Wu","year":"2022","unstructured":"Wu S, Luo H, Zhong Z, Ai Y, Zhao Y, Liang Q, Wang Y. Phytochemistry, pharmacology and quality control of Xiasangju: a traditional Chinese medicine formula. Front Pharmacol. 2022;13: 930813.","journal-title":"Front Pharmacol"},{"issue":"4","key":"1152_CR120","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1039\/b303745b","volume":"20","author":"X Chen","year":"2003","unstructured":"Chen X, Ung CY, Chen Y. Can an in silico drug-target search method be used to probe potential mechanisms of medicinal plant ingredients? Nat Prod Rep. 2003;20(4):432\u201344.","journal-title":"Nat Prod Rep"}],"updated-by":[{"DOI":"10.1186\/s40249-024-01180-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000}}],"container-title":["Infectious Diseases of Poverty"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-023-01152-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40249-023-01152-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-023-01152-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T10:09:09Z","timestamp":1707473349000},"score":1,"resource":{"primary":{"URL":"https:\/\/idpjournal.biomedcentral.com\/articles\/10.1186\/s40249-023-01152-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,11]]},"references-count":120,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1152"],"URL":"https:\/\/doi.org\/10.1186\/s40249-023-01152-6","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s40249-024-01180-w","asserted-by":"object"}]},"ISSN":["2049-9957"],"issn-type":[{"value":"2049-9957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,11]]},"assertion":[{"value":"22 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s40249-024-01180-w","URL":"https:\/\/doi.org\/10.1186\/s40249-024-01180-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they do not have any competing interests. Yangmu Huang and Yang Yang contributed to the work equally and should be regarded as co-first authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"115"}}